Research programme: folate-targeted cancer therapeutics - FLAG TherapeuticsAlternative Names: Folate-targeted anticancer compounds - Duquesne/FLAG; FTAC - FLAG Therapeutics
Latest Information Update: 06 Dec 2013
At a glance
- Originator Duquesne University
- Class Small molecules
- Mechanism of Action GPI-anchored folate receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Dec 2013 Preclinical trials in Cancer in USA (unspecified route)